Table 1.
Summary of intravenous iloprost clinical trials on Raynaud’s phenomenon (RP)
| Patients | Study design | Active treatment | Outcomes | References |
|---|---|---|---|---|
| 131 patients secondary RP | Randomized double-blind placebo-controlled | Iloprost 0.5–2 ng/kg/min IV infusion over 6 hours on 5 consecutive days | Frequency and severity reduced Physician’s rating of treatment effect improved No difference in digital ulcer healing |
20 |
| 35 patients secondary RP | Randomized double-blind placebo-controlled | Iloprost 0.5–2 ng/kg/min over 6 h on 5 consecutive days | Complete digital ulcer healing with iloprost No difference in frequency, duration, and severity |
23 |
| 13 patients secondary RP | Randomized double-blind placebo-controlled crossover | Iloprost 0.5–2 ng/kg/min over 6 h on 5 consecutive days | Frequency reduced No differences in duration or severity |
24 |
| 29 patients 26 secondary RP 3 primary RP | Randomized Double-blind placebo-controlled crossover | Iloprost 0.5–2 ng/kg/min over 6 h on 3 consecutive days | Frequency and severity reduced No difference in duration |
22 |
| 12 patients secondary RP | Randomized double-blind placebo-controlled crossover | Iloprost 1–3 ng/kg/min over 5 hours on 3 consecutive days | Frequency and severity decreased with iloprost | 21 |
| 55 patients secondary RP | Randomized double-blind | Iloprost 0.5 ng/kg/min or Iloprost 2 ng/kg/min over 6 h on 3 consecutive days | Frequency, severity, duration, and digital skin lesions reduced to similar extent with low dose and high dose | 25 |
| 46 patients secondary RP | Randomized single-blind | Iloprost 2 ng/kg/min over 8 h on 5 consecutive days, then over 8 hrs on 1 day every 6 weeks or Nifedipine 40 mg/day | Skin scores reduced to greater extent with iloprost than nifedipine Severity scores reduced with iloprost, but not with nifedipine |
28 |
| 23 patients secondary RP | Randomized double-blind double-dummy | Iloprost 0.5–2 ng/kg/min for 8 hours on 3 consecutive days, repeated at week 8 or Nifedipine 10 mg 3 times daily × 4 weeks, then 20 mg 3 times daily × 12 weeks | Frequency, duration, severity, and incidence of digital lesions reduced to comparable extent with iloprost and nifedipine | 27 |